News Release

Cleanascite™ Employed to Investigate Lipid Influence in Tumor-associated macrophages (TAMs)

MONMOUTH JUNCTION, NJ, January 9, 2023 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance technology for depletion of lipids from omental conditioned medium (OCM) to determine their influence on tumor-associated macrophages (TAMs)

Chan, David, et al. "Polyunsaturated Fatty Acids Promote Protumoral Macrophage Polarization via a RhoA-YAP1 Signaling Pathway in the Ovarian Cancer Microenvironment." (2022).

Tumor-associated macrophages (TAMs) are crucially associated with tumor development and progression; however, it remains unclear how the tumor microenvironment (TME) rewires the metabolic circuits and preferentially induces TAMs to polarize toward a protumoral phenotype. This study reports that polyunsaturated fatty acids (PUFAs) in malignant ascites promote protumoral M2-like TAMs deposition and facilitate peritoneal metastases of epithelial ovarian cancer (EOC). The article states “To selectively remove lipids, Cleanascite™ Lipid Removal Reagent (Biotech Support Group) was added to the omental conditioned medium (OCM) according to the manufacturer’s suggestions. … Intriguingly, the removal of free fatty acids in OCM by the Cleanascite™ attenuated lipid droplets deposition in M2-like MΦs and OCM-MΦs (Fig. 4A), indicating protumoral M2-like TAMs exhibited higher lipid accumulation and metabolism in the fatty acid-enriched OCM or the malignant ascites.”

“… Similarly, we demonstrated that the cellular ROS levels in OCM/AS-MΦs derived from PBMC MΦs were significantly upregulated, whereas the addition of Cleanascite™ mitigated the increased malignant ascites microenvironment (MAM)-mediated ROS level, indicating that the accumulation of UFAs in the MAM is responsible for the enhanced ROS production in TAMs (Fig. 4C). … Here, we further found …removal of lipids by Cleanascite™ remarkably prevented the reduction of YAP1 in OCM-MΦs (Fig. 5F), implying that the lipids within MAM facilitates protumoral M2-like TAMs polarization through the regulation of RhoA-YAP1 signaling cascade.” The article concludes that PUFAs are a key player in promoting tumor-infiltrated TAMs polarization that, in turn, facilitates EOC tumor growth and metastasis.

“This is now our fifth study whereby Cleanascite™ was used in evaluating the removal of free fatty acids in omental conditioned medium. These references along with over twenty others, show that Cleanascite™ can help identify a characteristic feature of in vitro cell response related to lipid removal. Unlike alternative methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations such as this, that need to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Link to view our case study, Lipid Removal for Phenotypic Cell Response in Cancer Research (biotechsupportgroup.com)

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Tumor-associated macrophages (TAMs), Macrophage polarization, omental conditioned medium, Cleanascite™, polyunsaturated fatty acids (PUFAs), malignant ascites

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com